Generic medicine

Erythropoietin: Brands, Price & Uses in Bangladesh

Q: What is Erythropoietin used for?

Erythropoietin is used to treat anemia (low red blood cell count) caused by chronic kidney disease, certain cancer chemotherapy regimens, zidovudine treatment in HIV infection, and to reduce the need for blood transfusions in some surgical patients. It works by stimulating the bone marrow to produce more red blood cells.

Q: Why does Erythropoietin have a boxed warning?

Erythropoietin carries an FDA boxed warning because, when used to raise hemoglobin above recommended target levels, it increases the risk of serious problems such as heart attack, stroke, blood clots, and death, and in cancer patients may increase the risk of tumor growth or recurrence and shorten survival. This is why your physician will use the lowest dose needed and monitor your hemoglobin regularly, rather than trying to normalize it.

Q: How is Erythropoietin given, and can I adjust my own dose?

Erythropoietin is given as an injection under the skin (subcutaneous) or into a vein (intravenous), usually by or under the supervision of a healthcare professional. Even if you are trained to self-inject at home, the dose and schedule must always be set and adjusted by your physician based on blood test results — never change your dose on your own.

Q: What are the common side effects of Erythropoietin?

The most common side effects of Erythropoietin include high blood pressure, joint or muscle pain, fever, headache, nausea, and reactions at the injection site. Your physician will monitor your blood pressure and hemoglobin levels regularly during treatment to catch and manage any problems early.

Q: Can Erythropoietin be used during pregnancy or breastfeeding?

Erythropoietin should be used during pregnancy only if clearly needed, when the potential benefit to the mother justifies the potential risk to the fetus, and only under a physician's guidance; certain multi-dose formulations containing benzyl alcohol must not be used in pregnant or breastfeeding women. Always consult your physician before using Erythropoietin if you are pregnant, planning pregnancy, or breastfeeding.

Q: What should I do if I think I've had too much Erythropoietin?

If you suspect an overdose of Erythropoietin , seek immediate medical attention or contact your physician, the nearest hospital emergency department, or a poison control center right away. Do not try to manage a suspected overdose at home, as it can raise your red blood cell count too quickly and lead to dangerous blood pressure or clotting problems.

Erythropoietin is an erythropoiesis-stimulating agent (ESA), a recombinant form of human erythropoietin that stimulates red blood cell production.

About Erythropoietin

Indications of Erythropoietin

Erythropoietin is an erythropoiesis-stimulating agent (ESA), a recombinant form of human erythropoietin that stimulates red blood cell production. It is FDA-approved and guideline-supported for the following established indications:

Anemia of chronic kidney disease (CKD): In patients on dialysis and patients not on dialysis, to reduce the need for red blood cell (RBC) transfusions.
Chemotherapy-induced anemia: In patients with non-myeloid malignancies whose anemia is due to the effect of concomitant myelosuppressive chemotherapy, when at least two additional months of chemotherapy are planned. Not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
Anemia due to zidovudine therapy in HIV-infected patients with endogenous serum erythropoietin levels ≤500 mUnits/mL and receiving zidovudine doses ≤4200 mg/week.
Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery who have a hemoglobin between 10 and 13 g/dL and are at high risk for perioperative blood loss.

Important limitations: Erythropoietin is not indicated and is not FDA-approved for improvement of quality of life, fatigue, or general well-being; for cancer patients receiving hormonal agents, biologic products, or radiotherapy only (without concomitant myelosuppressive chemotherapy); for patients who are able to donate autologous blood; or for use in patients undergoing cardiac or vascular surgery. Therapy should target the lowest dose sufficient to reduce the need for RBC transfusion, not to normalize hemoglobin (see Precautions and Warnings for the boxed warning).

Dosage & Administration of Erythropoietin

Dosing of Erythropoietin must be individualized by a physician based on the indication, baseline hemoglobin, rate and degree of hemoglobin rise, and clinical response. The goal is to use the lowest dose sufficient to reduce the need for RBC transfusion, not to normalize hemoglobin. Erythropoietin is given by intravenous or subcutaneous injection; it should never be self-adjusted by the patient without physician guidance.

Indication	Typical Starting Dose	Notes
Anemia of CKD (dialysis, adult)	50-100 Units/kg IV or SC, 3 times weekly	Initiate when hemoglobin <10 g/dL; reduce dose if hemoglobin approaches or exceeds 11 g/dL
Anemia of CKD (non-dialysis, adult)	50-100 Units/kg IV or SC, 3 times weekly	Consider therapy only if hemoglobin <10 g/dL; individualize to minimize transfusion need
Anemia of CKD (pediatric, ≥1 month)	50 Units/kg, 3 times weekly	Initiate when hemoglobin <10 g/dL; reduce dose if hemoglobin approaches or exceeds 12 g/dL
Zidovudine-associated anemia in HIV (adult)	100 Units/kg IV or SC, 3 times weekly	May increase by 50-100 Units/kg at 4-8 week intervals (up to 300 Units/kg) if response inadequate
Chemotherapy-induced anemia (adult)	150 Units/kg SC 3 times weekly, or 40,000 Units SC once weekly	Continue for at least 2 additional months of planned chemotherapy; discontinue after chemotherapy course ends
Chemotherapy-induced anemia (pediatric ≥5 years)	600 Units/kg IV once weekly	Reduce or withhold as per hemoglobin response
Perioperative (elective, non-cardiac, non-vascular surgery)	300 Units/kg/day SC for 15 days (10 days before, day of, and 4 days after surgery), or 600 Units/kg SC on days 21, 14, and 7 before surgery plus day of surgery	For patients with hemoglobin 10-13 g/dL at high risk of perioperative blood loss; venous thromboembolism prophylaxis is recommended

Hemoglobin should be monitored regularly (e.g., weekly to every 2-4 weeks) during therapy, and doses adjusted by the treating physician; the drug should be withheld if hemoglobin rises too rapidly or exceeds target levels. Iron status should be evaluated and corrected before and during treatment. Do not shake the solution, as vigorous shaking may denature the product.

Side Effects of Erythropoietin

Common and serious adverse effects reported with Erythropoietin include:

Very common: Hypertension (including severe hypertension), arthralgia/myalgia, fever, headache, nausea and vomiting, injection site pain/reactions, dizziness, fatigue.
Serious/important: Increased risk of death, myocardial infarction, stroke, and venous thromboembolism when hemoglobin is targeted above recommended levels (see Precautions and Warnings); pure red cell aplasia (rare, with prolonged use); seizures, particularly in CKD patients with rapid hematocrit rise; serious allergic reactions including anaphylaxis, angioedema, and bronchospasm; severe cutaneous reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis (rare).
Other reported effects: Cough, rash/urticaria, hyperkalemia, hyperglycemia, insomnia, depression, edema, and vascular access thrombosis in dialysis patients.

Contraindications of Erythropoietin

Erythropoietin is contraindicated in patients with:

Uncontrolled hypertension.
Pure red cell aplasia (PRCA) that begins after treatment with Erythropoietin or other erythropoietin protein drugs.
Known serious hypersensitivity to Erythropoietin or any of its components (e.g., anaphylaxis, angioedema).
Multi-dose (benzyl alcohol-preserved) formulations are contraindicated in neonates, infants, and pregnant or lactating women, due to risk of a fatal "gasping syndrome" from benzyl alcohol toxicity; single-dose, preservative-free formulations should be used in these populations if therapy is needed.

Frequently Asked Questions about Erythropoietin

What is Erythropoietin used for?

Erythropoietin is used to treat anemia (low red blood cell count) caused by chronic kidney disease, certain cancer chemotherapy regimens, zidovudine treatment in HIV infection, and to reduce the need for blood transfusions in some surgical patients. It works by stimulating the bone marrow to produce more red blood cells.

Why does Erythropoietin have a boxed warning?

Erythropoietin carries an FDA boxed warning because, when used to raise hemoglobin above recommended target levels, it increases the risk of serious problems such as heart attack, stroke, blood clots, and death, and in cancer patients may increase the risk of tumor growth or recurrence and shorten survival. This is why your physician will use the lowest dose needed and monitor your hemoglobin regularly, rather than trying to normalize it.

How is Erythropoietin given, and can I adjust my own dose?

Erythropoietin is given as an injection under the skin (subcutaneous) or into a vein (intravenous), usually by or under the supervision of a healthcare professional. Even if you are trained to self-inject at home, the dose and schedule must always be set and adjusted by your physician based on blood test results — never change your dose on your own.

What are the common side effects of Erythropoietin?

The most common side effects of Erythropoietin include high blood pressure, joint or muscle pain, fever, headache, nausea, and reactions at the injection site. Your physician will monitor your blood pressure and hemoglobin levels regularly during treatment to catch and manage any problems early.

Can Erythropoietin be used during pregnancy or breastfeeding?

Erythropoietin should be used during pregnancy only if clearly needed, when the potential benefit to the mother justifies the potential risk to the fetus, and only under a physician's guidance; certain multi-dose formulations containing benzyl alcohol must not be used in pregnant or breastfeeding women. Always consult your physician before using Erythropoietin if you are pregnant, planning pregnancy, or breastfeeding.

What should I do if I think I've had too much Erythropoietin?

If you suspect an overdose of Erythropoietin, seek immediate medical attention or contact your physician, the nearest hospital emergency department, or a poison control center right away. Do not try to manage a suspected overdose at home, as it can raise your red blood cell count too quickly and lead to dangerous blood pressure or clotting problems.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.